Fingerprint The fingerprint is based on mining the text of the scientific documents related to the associated persons. Based on that an index of weighted terms is created, which defines the key subjects of research unit

Lymphoma, Large B-Cell, Diffuse Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Non-Hodgkin's Lymphoma Medicine & Life Sciences
Survival Medicine & Life Sciences
Cisplatin Medicine & Life Sciences
T-Cell Lymphoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Profiles

No photo of Xiaonan Hong

Xiaonan Hong

Person: Academic

20002019

Research Output 2000 2019

2 Citations (Scopus)

Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study *

Robak, T., Huang, H-Q., Jin, J., Zhu, J., Liu, T., Samoilova, O., Pylypenko, H., Verhoef, G., Siritanaratkul, N., Osmanov, E., Pereira, J., Mayer, J., Hong, X., Okamoto, R., Pei, L., Rooney, B., van de Velde, H. & Cavalli, F., Jan 2 2019, In : Leukemia and Lymphoma. 60, 1, p. 172-179 8 p.

Research output: Contribution to journalArticle

Mantle-Cell Lymphoma
Survival
Prednisone
Doxorubicin
Cyclophosphamide

Bortezomib-based therapy for transplant-ineligible east asian patients with newly diagnosed mantle-cell lymphoma

Jin, J., Okamoto, R., Yoon, S. S., Shih, L. Y., Zhu, J., Liu, T., Hong, X., Pei, L., Rooney, B., van de Velde, H. & Huang, H-Q., Jul 6 2018, In : OncoTargets and Therapy. 11, p. 3869-3882 14 p.

Research output: Contribution to journalArticle

Mantle-Cell Lymphoma
Transplants
Vincristine
Stem Cell Transplantation
Disease-Free Survival

Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis

Liu, X., Wang, H., Wu, X., Hong, X. & Luo, Z., Feb 1 2018, In : Investigational New Drugs. 36, 1, p. 114-120 7 p.

Research output: Contribution to journalArticle

Aggressive Fibromatosis
Thalidomide
Doxorubicin
Serum Albumin
Disease-Free Survival